Fig. 1
Patient attrition. *Over 80% of the patients in the JAKi group were on tofacitinib. ADA, adalimumab; ETN, etanercept; JAKi, Janus kinase inhibitor
Fig. 1 | Arthritis Research & Therapy
Patient attrition. *Over 80% of the patients in the JAKi group were on tofacitinib. ADA, adalimumab; ETN, etanercept; JAKi, Janus kinase inhibitor